I sat down with Dr. Jerry Lanchbury - former Myriad CSO, genetic‑testing pioneer, and member of the Nucleus Scientific Advisory Board - to discuss the next frontiers in genetics: genetic optimization, polygenic risk, and the patient‑led shift that’s reshaping reproductive care.
We get into the history of genetic risk prediction, breakthroughs in embryo testing, explore how patients are reshaping the choice debate, and explain why this moment in genomics feels different than ever before.
0:00:00 - Dr. Lanchbury’s childhood and how he discovered genetics
0:06:46 - Early sequencing, the BRCA hunt, and Gemini Genomics
0:15:48 - Moving to the U.S. and scaling Myriad Genetics
0:30:13 - Gene‑patent fight, rise of multi‑gene panels, and pushback from academia
0:40:23 - Polygenic risk scores and why pre‑conception testing still overlooks many risks
0:55:06 - Embryo testing and Nucleus Embryo
1:04:16 - WGS for every newborn and related privacy concerns
1:09:50 - Nucleus’s product speed and increasing accessibility